论文部分内容阅读
目的探讨双水平气道无创正压通气(BiPAP)呼吸机治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并Ⅱ型呼吸衰竭的临床疗效。方法对2010年1月-2012年12月收治的80例AECOPD合并Ⅱ型呼吸衰竭患者的临床资料行回顾性分析,根据实施BiPAP呼吸机辅助通气治疗与否分为呼吸机研究组与对照组,每组各40例,比较生命体征及血气分析变化、疗效及医疗费用。结果研究组治疗前后,生命体征及血气分析各项指标比较显示出逐渐好转的一致性趋势(P<0.05);治疗3 d后,研究组患者生命体征及血气分析各项指标改善明显优于对照组(P<0.05)。较之对照组,研究组治疗总有效率增高,住院时间缩短,插管例数明减少,医疗费用减少(P<0.05)。结论 BiPAP无创呼吸机在改善AECOPD呼吸衰竭患者的生命体征、血气分析指标、气管插管率、住院时间等方面效果显著,值得推广。
Objective To investigate the clinical efficacy of bi-level airway noninvasive positive pressure ventilation (BiPAP) in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and type Ⅱ respiratory failure. Methods The clinical data of 80 AECOPD patients with type Ⅱ respiratory failure admitted to our hospital from January 2010 to December 2012 were retrospectively analyzed. According to whether ventilator-assisted ventilation was performed with BiPAP or not, the patients were divided into ventilator study group and control group, Each group of 40 cases, compare vital signs and blood gas analysis changes, efficacy and medical costs. Results Before and after treatment, vital signs and blood gas analysis showed a trend of consistency (P <0.05). After 3 days of treatment, the vital signs and blood gas analysis indexes of the study group were significantly better than those of the control Group (P <0.05). Compared with the control group, the study group increased the total effective rate of treatment, shorter hospital stay, reduced intubation cases, and reduced medical costs (P <0.05). Conclusion BiPAP noninvasive ventilator is effective in improving vital signs, blood gas analysis indexes, tracheal intubation rate and hospitalization time in patients with AECOPD respiratory failure. It is worth promoting.